CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy.
- DOI
- 10.1016/j.ppl.2026.07.001
- Published
- 2026 Aug
- Container
- Protein and peptide letters
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ppl.2026.07.001,
title = {CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy.},
author = {Wu M and Feng X and Huang W and Wu Y and Cui J},
year = {2026},
journal = {Protein and peptide letters},
doi = {10.1016/j.ppl.2026.07.001},
url = {https://doi.org/10.1016/j.ppl.2026.07.001}
}RIS
TY - JOUR TI - CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy. AU - Wu M AU - Feng X AU - Huang W AU - Wu Y AU - Cui J PY - 2026 JO - Protein and peptide letters DO - 10.1016/j.ppl.2026.07.001 UR - https://doi.org/10.1016/j.ppl.2026.07.001 ER -
APA
M, W., X, F., W, H., Y, W., & J, C. (2026). CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy.. Protein and peptide letters. https://doi.org/10.1016/j.ppl.2026.07.001
Source records
- pubmed · retrieved 2026-09-26T14:27:13.725Z